Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...
The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...
GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by ...
Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...
Clinical Trials Arena on MSN
Ocugen’s GA gene therapy garners mixed sentiments on 12-month Phase II readout
While OCU410’s efficacy was not as strong as it was in a preliminary analysis, analysts still foresee the drug carving a ...
Ocugen (OCGN) shares lost ~12% in the premarket on Tuesday after the company announced 12-month data from a mid-stage trial ...
NEW YORK CITY -- Subretinal drusenoid deposits (SDD) had a significant association with underlying cardiovascular disease (CVD), adding a missing link between age-related macular degeneration (AMD) ...
A presentation during the recent American Society of Retina Specialists (ASRS) annual meeting highlighted a study that demonstrated that patients with a specific symptom of age-related macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results